ReviewInternational journal of general medicine2015
Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy.
Review in International journal of general medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Four-dimensional flow MRI-based prediction of minimal hepatic encephalopathy in patients with liver cirrhosis.Abdominal radiology (New York) · 2026Article
- Management of Refractory Hepatic Encephalopathy.Digestive diseases and sciences · 2026Review
- Quality of life, anxiety, and depression improve at one-year after liver transplantation in patients with advanced liver disease.Frontiers in transplantation · 2024Article
- Animal naming test is a simple and valid tool for detecting covert hepatic encephalopathy and predicting outcomes in Chinese-speaking regions: a preliminary study.Annals of medicine · 2023Article
- Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II).Frontline gastroenterology · 2023Article
- Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.Journal of managed care & specialty pharmacy · 2020Article
- Protective effects of synbiotic soymilk fortified with whey protein concentrate and zinc sulfate against bile duct ligated-induced hepatic encephalopathy.Gastroenterology and hepatology from bed to bench · 2020Article
- Outpatient telephonic transitional care after hospital discharge improves survival in cirrhotic patients.World journal of hepatology · 2019Article
- The utility of neuropsychological consultation in identifying medical inpatients with suspected cognitive impairment at risk for greater hospital utilization.The Clinical neuropsychologist · 2019Article
- Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy.World journal of gastroenterology · 2017Article
- The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS).Frontline gastroenterology · 2017Article
- Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions.Gut and liver · 2016Review
- The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.Hepatology (Baltimore, Md.) · 2016Article
- Health-related quality of life and affective status in liver transplant recipients and patients on the waiting list with low MELD scores.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvert hepatic encephalopathy (HE), which is associated with neuropsychiatric symptoms and neuromuscular dysfunction in patients with liver cirrhosis, is often managed in the hospital setting. Approximately 60% of eligible patients do not receive prophylactic therapy after an overt HE episode.
objectiveThe aim of this review is to evaluate the impact of rehospitalization on costs and clinical outcomes in HE.
methodsA PubMed search of English-language articles through July 9, 2014 was conducted, and bibliographies of identified publications were reviewed. Abstracts from relevant professional society meetings from 2010 to 2014 were searched. The selected references and abstracts reported on the prevalence, costs, or clinical consequences of rehospitalization in adults with HE. DATA SYNTHESIS: HE is a key reason for readmission among patients hospitalized for complications of cirrhosis. Almost 40% of patients previously hospitalized for HE may be readmitted within 1 year for HE-related reasons. Furthermore, in-hospital US mortality for patients admitted for HE is about 7% to 15%. Recurrent HE and hospitalization for cirrhosis complications are associated with impaired quality of life. In addition, recurrences (especially those requiring hospitalization) may contribute to persistent cognitive deficits (eg, impairments in reaction time, attention, and working memory) after resolution of an acute episode of overt HE.
conclusionThe economic and clinical consequences of rehospitalization for patients with overt HE underscore the importance of secondary prevention and highlight the need to identify reasons for the undertreatment of patients after hospitalization for overt HE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.